Targeting the Hedgehog Pathway. Role in Cancer and Clinical Implications of Its Inhibition

Hematology/Oncology Clinics of North America

Volumn 26, Issue 3, 2012, Pages 565-588

  Cohen, Deirdre J ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Drugs; Hedgehog; Pathway; Therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BMS 833923; BOSUTINIB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPAMINE; DASATINIB; ERISMODEGIB; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GAMMA SECRETASE INHIBITOR; GEMCITABINE; IPI 926; IRINOTECAN; ITRACONAZOLE; LEQ 506; LEUPRORELIN; LY 2940680; OXALIPLATIN; PACLITAXEL; PEMETREXED; PF 04449913; PLACEBO; RO 4929097; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISMODEGIB; XL 139;

BASAL CELL CARCINOMA; CANCER THERAPY; CHONDROSARCOMA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG BIOAVAILABILITY; DRUG MECHANISM; EMBRYO DEVELOPMENT; GASTROINTESTINAL CARCINOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG SMALL CELL CANCER; MEDULLOBLASTOMA; MULTIPLE MYELOMA; MYELOFIBROSIS; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREAS CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; HEDGEHOG PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84859955497     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.01.005     Document Type: Review

References (114)

1. Ingham P.W., Nakano Y., Seger C. Mechanisms and functions of Hedgehog signalling across the metazoa. Nat Rev Genet 2011, 12(6):393-406.
2. Ingham P.W., McMahon A.P. Hedgehog signaling in animal development: paradigms and principles. Genes Dev 2001, 15(23):3059-3087.
3. Nusslein-Volhard C., Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature 1980, 287(5785):795-801.
4. Hooper J.E., Scott M.P. Communicating with Hedgehogs. Nat Rev Mol Cell Biol 2005, 6(4):306-317.
5. Rubin L.L., de Sauvage F.J. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006, 5(12):1026-1033.
6. Belloni E., Muenke M., Roessler E., et al. Identification of Sonic hedgehog as a candidate gene responsible for holoprosencephaly. Nat Genet 1996, 14(3):353-356.
7. Roessler E., Belloni E., Gaudenz K., et al. Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. Nat Genet 1996, 14(3):357-360.
8. Adolphe C., Narang M., Ellis T., et al. An in vivo comparative study of sonic, desert and Indian hedgehog reveals that hedgehog pathway activity regulates epidermal stem cell homeostasis. Development 2004, 131(20):5009-5019.
9. van den Brink G.R. Hedgehog signaling in development and homeostasis of the gastrointestinal tract. Physiol Rev 2007, 87(4):1343-1375.
10. Rockel J.S., Alman B.A. Don't hedge your bets: hedgehog signaling as a central mediator of endochondral bone development and cartilage diseases. J Orthop Res 2011, 29(6):810-815.
11. Epstein E.H. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008, 8(10):743-754.
12. Mann R.K., Beachy P.A. Novel lipid modifications of secreted protein signals. Annu Rev Biochem 2004, 73:891-923.
13. Gallet A. Hedgehog morphogen: from secretion to reception. Trends Cell Biol 2011, 21(4):238-246.
14. Buglino J.A., Resh M.D. Identification of conserved regions and residues within Hedgehog acyltransferase critical for palmitoylation of Sonic Hedgehog. PLoS One 2010, 5(6):e11195.
15. Kawakami T., Kawcak T., Li Y.J., et al. Mouse dispatched mutants fail to distribute hedgehog proteins and are defective in hedgehog signaling. Development 2002, 129(24):5753-5765.
16. Ma Y., Erkner A., Gong R., et al. Hedgehog-mediated patterning of the mammalian embryo requires transporter-like function of dispatched. Cell 2002, 111(1):63-75.
17. Taipale J., Cooper M.K., Maiti T., et al. Patched acts catalytically to suppress the activity of Smoothened. Nature 2002, 418(6900):892-897.
18. Yavari A., Nagaraj R., Owusu-Ansah E., et al. Role of lipid metabolism in smoothened derepression in hedgehog signaling. Dev Cell 2010, 19(1):54-65.
19. Khaliullina H., Panakova D., Eugster C., et al. Patched regulates Smoothened trafficking using lipoprotein-derived lipids. Development 2009, 136(24):4111-4121.
20. Callejo A., Culi J., Guerrero I. Patched, the receptor of Hedgehog, is a lipoprotein receptor. Proc Natl Acad Sci U S A 2008, 105(3):912-917.
21. Bijlsma M.F., Spek C.A., Zivkovic D., et al. Repression of smoothened by patched-dependent (pro-) vitamin D3 secretion. PLoS Biol 2006, 4(8):e232.
22. Michaud E.J., Yoder B.K. The primary cilium in cell signaling and cancer. Cancer Res 2006, 66(13):6463-6467.
23. Huangfu D., Liu A., Rakeman A.S., et al. Hedgehog signalling in the mouse requires intraflagellar transport proteins. Nature 2003, 426(6962):83-87.
24. Cortellino S., Wang C., Wang B., et al. Defective ciliogenesis, embryonic lethality and severe impairment of the Sonic Hedgehog pathway caused by inactivation of the mouse complex A intraflagellar transport gene Ift122/Wdr10, partially overlapping with the DNA repair gene Med1/Mbd4. Dev Biol 2009, 325(1):225-237.
25. Bai C.B., Stephen D., Joyner A.L. All mouse ventral spinal cord patterning by hedgehog is Gli dependent and involves an activator function of Gli3. Dev Cell 2004, 6(1):103-115.
26. Bhatia N., Thiyagarajan S., Elcheva I., et al. Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin ligase. J Biol Chem 2006, 281(28):19320-19326.
27. Wang B., Li Y. Evidence for the direct involvement of {beta}TrCP in Gli3 protein processing. Proc Natl Acad Sci U S A 2006, 103(1):33-38.
28. Katoh Y., Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 2009, 9(7):873-886.
29. Kinzler K.W., Vogelstein B. The GLI gene encodes a nuclear protein which binds specific sequences in the human genome. Mol Cell Biol 1990, 10(2):634-642.
30. Sasaki H., Hui C., Nakafuku M., et al. A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. Development 1997, 124(7):1313-1322.
31. Kinzler K.W., Ruppert J.M., Bigner S.H., et al. The GLI gene is a member of the Kruppel family of zinc finger proteins. Nature 1988, 332(6162):371-374.
32. Ruiz i Altaba A., Mas C., Stecca B. The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol 2007, 17(9):438-447.
33. Yang L., Xie G., Fan Q., et al. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 2010, 29(4):469-481.
34. Barnfield P.C., Zhang X., Thanabalasingham V., et al. Negative regulation of Gli1 and Gli2 activator function by Suppressor of fused through multiple mechanisms. Differentiation 2005, 73(8):397-405.
35. Kise Y., Morinaka A., Teglund S., et al. Sufu recruits GSK3beta for efficient processing of Gli3. Biochem Biophys Res Commun 2009, 387(3):569-574.
36. Cheng S.Y., Bishop J.M. Suppressor of Fused represses Gli-mediated transcription by recruiting the SAP18-mSin3 corepressor complex. Proc Natl Acad Sci U S A 2002, 99(8):5442-5447.
37. Hahn H., Wicking C., Zaphiropoulous P.G., et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85(6):841-851.
38. Johnson R.L., Rothman A.L., Xie J., et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996, 272(5268):1668-1671.
39. Gailani M.R., Stahle-Backdahl M., Leffell D.J., et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996, 14(1):78-81.
40. Reifenberger J., Wolter M., Weber R.G., et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998, 58(9):1798-1803.
41. Xie J., Johnson R.L., Zhang X., et al. Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res 1997, 57(12):2369-2372.
42. Reifenberger J., Wolter M., Knobbe C.B., et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005, 152(1):43-51.
43. Zhang Y., Kalderon D. Hedgehog acts as a somatic stem cell factor in the Drosophila ovary. Nature 2001, 410(6828):599-604.
44. Takebe N., Harris P.J., Warren R.Q., et al. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011, 8(2):97-106.
45. Merchant A.A., Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010, 16(12):3130-3140.
46. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8(10):755-768.
47. Li C., Heidt D.G., Dalerba P., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67(3):1030-1037.
48. Theunissen J.W., de Sauvage F.J. Paracrine Hedgehog signaling in cancer. Cancer Res 2009, 69(15):6007-6010.
49. Dierks C., Beigi R., Guo G.R., et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14(3):238-249.
50. Clement V., Sanchez P., de Tribolet N., et al. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007, 17(2):165-172.
51. Peacock C.D., Wang Q., Gesell G.S., et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A 2007, 104(10):4048-4053.
52. Liu S., Dontu G., Mantle I.D., et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006, 66(12):6063-6071.
53. Binns W., James L.F., Shupe J.L., et al. A congenital cyclopian-type malformation in lambs induced by maternal ingestion of a range plant, Veratrum californicum. Am J Vet Res 1963, 24:1164-1175.
54. Cooper M.K., Porter J.A., Young K.E., et al. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 1998, 280(5369):1603-1607.
55. Chen J.K., Taipale J., Cooper M.K., et al. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 2002, 16(21):2743-2748.
56. Yauch R.L., Gould S.E., Scales S.J., et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455(7211):406-410.
57. Williams J.A. Hedgehog signaling pathway as a target for therapeutic intervention in basal cell carcinoma. Drug News Perspect 2003, 16(10):657-662.
58. Tremblay M.R., Nevalainen M., Nair S.J., et al. Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists. J Med Chem 2008, 51(21):6646-6649.
59. Von Hoff D.D., LoRusso P.M., Rudin C.M., et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009, 361(12):1164-1172.
60. Siu L.L., Papadopoulos K., Alberts S.R., et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors [abstract]. J Clin Oncol 2010, 28(15 Suppl). abstr 2501.
61. Tawbi H.A., Ahnert J.R., Dummer R., et al. Phase I study of LDE225 in advanced solid tumors: updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation. J Clin Oncol 2011, 29(15 Suppl). abstr 3062.
62. Rudin C.M., Jimeno A., Miller W.H., et al. A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. J Clin Oncol 2011, 29(15 Suppl). abstr 3014.
63. Stanton B.Z., Peng L.F., Maloof N., et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol 2009, 5(3):154-156.
64. Lauth M., Bergstrom A., Shimokawa T., et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A 2007, 104(20):8455-8460.
65. Hyman J.M., Firestone A.J., Heine V.M., et al. Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci U S A 2009, 106(33):14132-14137.
66. Kim J., Lee J.J., Gardner D., et al. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A 2010, 107(30):13432-13437.
67. Kim J., Tang J.Y., Gong R., et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010, 17(4):388-399.
68. Xie J., Murone M., Luoh S.M., et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998, 391(6662):90-92.
69. Oro A.E., Higgins K.M., Hu Z., et al. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 1997, 276(5313):817-821.
70. Nilsson M., Unden A.B., Krause D., et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci U S A 2000, 97(7):3438-3443.
71. Aszterbaum M., Epstein J., Oro A., et al. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat Med 1999, 5(11):1285-1291.
72. Williams J.A., Guicherit O.M., Zaharian B.I., et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci U S A 2003, 100(8):4616-4621.
73. Tang T., Tang J.Y., Li D., et al. Targeting superficial or nodular basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res 2011, 17(10):3378-3387.
74. LoRusso P.M., Rudin C.M., Reddy J.C., et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011, 17(8):2502-2511.
75. Sekulic A., Migden M., Oro A., et al. Abstracts of the 7th European Association of Dermato-Oncology (EADO) Congress. J20-23, 2011. Nantes, France. Melanoma Res 2011, 21(Suppl):e1-e63.
76. Tang J.Y., Mackay-Wiggan J.M., Aszterbaum M., et al. An investigator-initiated, phase II randomized, double-blind, placebo-controlled trial of GDC-0449 for prevention of BCCs in basal cell nevus syndrome (BCNS) patients 2011, American Association for Cancer Research, Orlando (FL).
77. Skvara H., Kalthoff F., Meingassner J.G., et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011, 131(8):1735-1744.
78. Romer J.T., Kimura H., Magdaleno S., et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 2004, 6(3):229-240.
79. Goodrich L.V., Milenkovic L., Higgins K.M., et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997, 277(5329):1109-1113.
80. Lee Y., Miller H.L., Jensen P., et al. A molecular fingerprint for medulloblastoma. Cancer Res 2003, 63(17):5428-5437.
81. Thompson M.C., Fuller C., Hogg T.L., et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006, 24(12):1924-1931.
82. Rudin C.M., Hann C.L., Laterra J., et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009, 361(12):1173-1178.
83. Yauch R.L., Dijkgraaf G.J., Alicke B., et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326(5952):572-574.
84. Pepicelli C.V., Lewis P.M., McMahon A.P. Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Curr Biol 1998, 8(19):1083-1086.
85. Watkins D.N., Berman D.M., Burkholder S.G., et al. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003, 422(6929):313-317.
86. Lum L., Beachy P.A. The Hedgehog response network: sensors, switches, and routers. Science 2004, 304(5678):1755-1759.
87. Yoo Y.A., Kang M.H., Kim J.S., et al. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway. Carcinogenesis 2008, 29(3):480-490.
88. Karhadkar S.S., Bova G.S., Abdallah N., et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004, 431(7009):707-712.
89. Feldmann G., Dhara S., Fendrich V., et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007, 67(5):2187-2196.
90. Feldmann G., Fendrich V., McGovern K., et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008, 7(9):2725-2735.
91. Ma X., Sheng T., Zhang Y., et al. Hedgehog signaling is activated in subsets of esophageal cancers. Int J Cancer 2006, 118(1):139-148.
92. Thayer S.P., di Magliano M.P., Heiser P.W., et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425(6960):851-856.
93. Zhao C., Chen A., Jamieson C.H., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458(7239):776-779.
94. Sims-Mourtada J., Izzo J.G., Apisarnthanarax S., et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 2006, 12(21):6565-6572.
95. Yoshikawa R., Nakano Y., Tao L., et al. Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy. Br J Cancer 2008, 98(10):1670-1674.
96. Olive K.P., Jacobetz M.A., Davidson C.J., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324(5933):1457-1461.
97. Berman D.M., Karhadkar S.S., Maitra A., et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003, 425(6960):846-851.
98. Qualtrough D., Buda A., Gaffield W., et al. Hedgehog signalling in colorectal tumour cells: induction of apoptosis with cyclopamine treatment. Int J Cancer 2004, 110(6):831-837.
99. Stecca B., Mas C., Clement V., et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A 2007, 104(14):5895-5900.
100. Tian H., Callahan C.A., DuPree K.J., et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A 2009, 106(11):4254-4259.
101. Nolan-Stevaux O., Lau J., Truitt M.L., et al. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 2009, 23(1):24-36.
102. Fan L., Pepicelli C.V., Dibble C.C., et al. Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 2004, 145(8):3961-3970.
103. Bailey J.M., Swanson B.J., Hamada T., et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 2008, 14(19):5995-6004.
104. Yamazaki M., Nakamura K., Mizukami Y., et al. Sonic hedgehog derived from human pancreatic cancer cells augments angiogenic function of endothelial progenitor cells. Cancer Sci 2008, 99(6):1131-1138.
105. Hegde G.V., Peterson K.J., Emanuel K., et al. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target. Mol Cancer Res 2008, 6(12):1928-1936.
106. Desch P., Asslaber D., Kern D., et al. Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells. Oncogene 2010, 29(35):4885-4895.
107. Berlin J.D., Bendell J., Hart L., et al. A phase 2, randomized, double-blind, placebo-controlled study of hedgehog pathway inhibitor (HPI) GDC-0449 in patients with previously untreated metastatic colorectal cancer (mCRC) [abstract LBA21]. Ann Oncol 2010, 21(Suppl 8). viii10.
108. Chen W., Tang T., Eastham-Anderson J., et al. Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells. Proc Natl Acad Sci U S A 2011, 108(23):9589-9594.
109. Kaye S.B., Fehrenbacher L., Holloway R., et al. A phase 2, randomized, placebo-controlled study of hedgehog (HH) pathway inhibitor GDC-0449 as maintenance therapy in patients with ovarian cancer in 2nd or 3rd complete remission. Ann Oncol 2010, 21(Suppl 8).
110. Metcalfe C., de Sauvage F.J. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 2011, 71(15):5057-5061.
111. Ji Z., Mei F.C., Xie J., et al. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 2007, 282(19):14048-14055.
112. Laner-Plamberger S., Kaser A., Paulischta M., et al. Cooperation between GLI and JUN enhances transcription of JUN and selected GLI target genes. Oncogene 2009, 28(13):1639-1651.
113. Stecca B., Ruiz I., Altaba A. A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J 2009, 28(6):663-676.
114. Buonamici S., Williams J., Morrissey M., et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010, 2(51):51ra70.